Context Therapeutics (CNTX) announced the amendment of the company’s exclusive license agreement, dated September 23, 2024, with BioAtla (BCAB). The amendment removes all future milestone and royalty obligations owed by the company for CT-202, the company’s Nectin-4 x CD3 T cell engager, in exchange for a $4.5M upfront payment, and a second and final $2M payment due by August 1, 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTX:
- Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
- Context Therapeutics reports Q1 EPS (9c), consensus (12c)
- Context Therapeutics settles governance lawsuit with mootness fee
- Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
- Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating